279 related articles for article (PubMed ID: 28442256)
21. A Comprehensive Review of Aminochalcones.
Irfan R; Mousavi S; Alazmi M; Saleem RSZ
Molecules; 2020 Nov; 25(22):. PubMed ID: 33213087
[TBL] [Abstract][Full Text] [Related]
22. Trends in utilization of the pharmacological potential of chalcones.
Batovska DI; Todorova IT
Curr Clin Pharmacol; 2010 Feb; 5(1):1-29. PubMed ID: 19891604
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of C3 substituted chalcone-based derivatives of 7-azaindole as protein kinase inhibitors.
Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Beteck RM
Chem Biol Drug Des; 2020 Dec; 96(6):1395-1407. PubMed ID: 32558155
[TBL] [Abstract][Full Text] [Related]
24. Chalcones: Synthetic Chemistry Follows Where Nature Leads.
Jasim HA; Nahar L; Jasim MA; Moore SA; Ritchie KJ; Sarker SD
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439870
[TBL] [Abstract][Full Text] [Related]
25. Antiplasmodial dimeric chalcone derivatives from the roots of Uvaria siamensis.
Salae AW; Chairerk O; Sukkoet P; Chairat T; Prawat U; Tuntiwachwuttikul P; Chalermglin P; Ruchirawat S
Phytochemistry; 2017 Mar; 135():135-143. PubMed ID: 27989370
[TBL] [Abstract][Full Text] [Related]
26. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.
Mai CW; Yaeghoobi M; Abd-Rahman N; Kang YB; Pichika MR
Eur J Med Chem; 2014 Apr; 77():378-87. PubMed ID: 24675137
[TBL] [Abstract][Full Text] [Related]
27. Chalcones in cancer: understanding their role in terms of QSAR. II part.
Repanas A; Katsori AM; Hadjipavlou-Litina D
Mini Rev Med Chem; 2013 Jun; 13(7):952-70. PubMed ID: 22876949
[TBL] [Abstract][Full Text] [Related]
28. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer.
WalyEldeen AA; Sabet S; El-Shorbagy HM; Abdelhamid IA; Ibrahim SA
Chem Biol Interact; 2023 Jan; 369():110297. PubMed ID: 36496109
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic activity of substituted chalcones in terms of molecular electronic properties.
Kupcewicz B; Jarzęcki AA; Małecka M; Krajewska U; Rozalski M
Bioorg Med Chem Lett; 2014 Sep; 24(17):4260-5. PubMed ID: 25091929
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents.
Reddy MV; Su CR; Chiou WF; Liu YN; Chen RY; Bastow KF; Lee KH; Wu TS
Bioorg Med Chem; 2008 Aug; 16(15):7358-70. PubMed ID: 18602831
[TBL] [Abstract][Full Text] [Related]
31. Flavonoids: promising natural compounds against viral infections.
Zakaryan H; Arabyan E; Oo A; Zandi K
Arch Virol; 2017 Sep; 162(9):2539-2551. PubMed ID: 28547385
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents.
Bandgar BP; Gawande SS; Bodade RG; Totre JV; Khobragade CN
Bioorg Med Chem; 2010 Feb; 18(3):1364-70. PubMed ID: 20064725
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of indolyl chalcones as antitumor agents.
Kumar D; Kumar NM; Akamatsu K; Kusaka E; Harada H; Ito T
Bioorg Med Chem Lett; 2010 Jul; 20(13):3916-9. PubMed ID: 20627724
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and structure-activity relationship studies of furan-ring fused chalcones as antiproliferative agents.
Saito Y; Kishimoto M; Yoshizawa Y; Kawaii S
Anticancer Res; 2015 Feb; 35(2):811-7. PubMed ID: 25667461
[TBL] [Abstract][Full Text] [Related]
35. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
Boumendjel A; Boccard J; Carrupt PA; Nicolle E; Blanc M; Geze A; Choisnard L; Wouessidjewe D; Matera EL; Dumontet C
J Med Chem; 2008 Apr; 51(7):2307-10. PubMed ID: 18293907
[TBL] [Abstract][Full Text] [Related]
36. Involvement of extrinsic and intrinsic apoptotic pathways together with endoplasmic reticulum stress in cell death induced by naphthylchalcones in a leukemic cell line: advantages of multi-target action.
Winter E; Chiaradia LD; Silva AH; Nunes RJ; Yunes RA; Creczynski-Pasa TB
Toxicol In Vitro; 2014 Aug; 28(5):769-77. PubMed ID: 24583196
[TBL] [Abstract][Full Text] [Related]
37. Advances in chalcones with anticancer activities.
Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
[TBL] [Abstract][Full Text] [Related]
38. A review of anti-infective and anti-inflammatory chalcones.
Nowakowska Z
Eur J Med Chem; 2007 Feb; 42(2):125-37. PubMed ID: 17112640
[TBL] [Abstract][Full Text] [Related]
39. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases.
Shin SY; Yoon H; Hwang D; Ahn S; Kim DW; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2013 Nov; 21(22):7018-24. PubMed ID: 24095020
[TBL] [Abstract][Full Text] [Related]
40. Natural Chalcones and Their Derivatives Target the Tumor Microenvironment in Colon Cancer.
Malla RR; Siragam S; Dadi V; Seetini B
Crit Rev Immunol; 2022; 42(6):27-39. PubMed ID: 37082949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
